This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Ryanair Q3 total op. revenues (pre-exceptional) +9% YoY, op. expenses +20%, swings to €83.6m pre-tax loss (€22.1m loss pre-exceptional) vs £112.9m profit a year ago. FY guidance unchanged (“cannot rule out further cuts to air fares & slightly lower FY guidance in case of unexpected Brexit developments”). Will set out CEO succession plan before Sept ‘19 AGM. Jan passengers +11% (+8% rolling 12-months), load factor flat, Average fares -6%.
Ferrexpo conducting independent review into unexplained accounting discrepancies on bank statements of the Blooming Land charity in Ukraine, to whom it donated $9.5m in H1’18. Board cannot guarantee review will be completed by 20 Mar for FY results, or complete favourably. Deloitte may qualify or otherwise modify audit opinion relating to FY 2018 accounts.
Serco signs £560m pact with Bupa to support Australian defence force, through the provision of National Garrison Health Services, from 1 July, initially for 6 years with the possibility of 4x 1-year extensions. Had said in negotiations on 14 Jan.
Indivior enters agreement with Alvogen preventing it from US use/offer/sale/importation of Indivior’s generic generic buprenorphine and naloxone sublingual film product unless/until preliminary injunction against Dr. Reddy’s is lifted.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.Prepared by Michael van Dulken, Head of Research